Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
AstraZeneca
Colorcon
Harvard Business School
Moodys

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,741,374

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,741,374 protect, and when does it expire?

Patent 7,741,374 protects FIBRICOR and is included in one NDA.

Summary for Patent: 7,741,374
Title:Methods of use of fenofibric acid
Abstract:Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
Inventor(s): Arnold; Kristin Anne (Morrisville, PA), Feng; Hengsheng (Cherry Hill, NJ)
Assignee: Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:12/556,644
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,741,374

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-001 Aug 14, 2009 RX Yes No   Start Trial   Start Trial ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS   Start Trial
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-001 Aug 14, 2009 RX Yes No   Start Trial   Start Trial ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA   Start Trial
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-002 Aug 14, 2009 RX Yes Yes   Start Trial   Start Trial ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS   Start Trial
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-002 Aug 14, 2009 RX Yes Yes   Start Trial   Start Trial ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Colorcon
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.